ArticleCureus2026
Facial Melanosis: A Clinico-Dermoscopic Evaluation and Quality of Life Assessment.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFacial melanoses (FM) represent a heterogeneous group of pigmentary disorders characterized by altered facial pigmentation, including melasma, lichen planus pigmentosus (LPP), Riehl's melanosis, erythema dyschromicum perstans, and others. These conditions constitute a major proportion of dermatology outpatient visits and, despite being largely asymptomatic, exert a substantial negative impact on quality of life (QoL) due to cosmetic disfigurement. The etiology of many forms of FM remains unclear, and studies correlating clinical, dermatoscopic, and QoL parameters are limited. STUDY
designA prospective observational study. PRIMARY
objectiveTo evaluate the change in QoL in patients with FM after three months of diagnosis-based treatment, using the Dermatology Life Quality Index (DLQI) and Melasma Quality of Life Scale (MELASQoL) scores. SECONDARY
objectivesTo describe the clinical profile of patients with FM and to identify the etiological spectrum of the condition in the study population. The study also aimed to assess Wood's lamp findings and dermoscopic patterns of the lesions and to document histopathological findings in selected cases, correlating them with the clinical and dermoscopic features wherever possible. MATERIALS AND
methodsA prospective observational study was conducted among 50 patients aged 18-60 years with FM involving more than 50% of the facial surface area, attending a tertiary care hospital. Detailed clinical evaluation, Wood's lamp examination, and dermatoscopic assessment were performed in all patients. QoL was assessed using the DLQI and MELASQoL at baseline and after three months of treatment. Histopathology was undertaken where clinically indicated. Statistical analysis was performed using SPSS v28 (IBM Corp., Armonk, NY).
resultsThe mean age of participants was 35.7 years; 38 patients (76%) were female, yielding a female-to-male ratio of 3.16:1. LPP was the most common diagnosis, found in 26 (52%) patients, followed by melasma, found in nine (18%) patients. Dermatoscopy most frequently demonstrated an accentuated reticular pattern in 21 (42%) patients and globular pigmentation in 18 (35%) patients, with gray granules correlating with dermal pigmentation in LPP. The mean DLQI score improved from 7.86±6.64 at baseline to 4.78±6.12 at three months, while the mean MELASQoL score decreased from 36.04±21.03 to 26.36±17.42 (p<0.001 for both). Hypothyroidism was the most common associated comorbidity, observed in five (10%) patients. LIMITATIONS: Histopathological confirmation was done in limited cases, and the single-center design with a modest sample size may limit generalizability.
conclusionFM significantly impairs QoL, particularly among young women. LPP emerged as the predominant cause in our study. Dermatoscopy is a valuable non-invasive tool for assessing pigment depth and guiding management. DLQI and MELASQoL are effective instruments for monitoring therapeutic outcomes. Early diagnosis, appropriate counseling, and multimodal therapy are essential to improve patient well-being.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.